Health Populi November 14, 2024
Jane Sarasohn-Kahn

For health care, there are many uncertainties as we reflect, one week after the 2024 U.S. elections, on probably policy and market impacts that we can expect in 2025 and beyond. In today’s Health Populi post, I’ll reflect on the first of several certainties we-know-we-know about U.S. health citizens and key factors shaping the American health ecosystem.

In this first of several posts on “What Stays True for U.S. Health Care Post #Election2024,” I’ll focus on U.S. consumer dissatisfaction with drug prices — across political party identification.

Let’s set the context with data from a recently-published study from Navitus Health Solutions exploring 2,000 U.S. insured consumers’ perspectives on prescription drug pricing and the role of PBMs (pharmacy benefit managers)....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech
Are you affected by the Trump administration’s pause on health communications, science meetings, and reviews?
The Trump administration's AI strategy
New Trump Executive Order Creates AI Challenges For Corporate Boards
US sets WHO exit date
This Week in AI: Trump Repeals Biden AI Rules but Launches Stargate

Share This Article